Ozapic approved in Canada to slow down kidney fall, to prevent heart disease
Health Canada has approved the ozmpic to reduce the risk of fall in further kidney in patients with type 2 diabetes.
Some forms of chronic kidney disease are developed among 30 to 50 percent of people with type 2 diabetes.
An international clinical trial called Flow, the renal risk deteriorated or failed, showed that a placebo injection was 24 percent lower in patients with ozmpic compared to injections.
Patients taking the drug were also less likely to die of heart disease – another condition that affects many diabetic patients.
The study, funded by Ozapic manufacturer Novo Nordisk was reviewed and published by Novo Nordisk New England Journal of Medicine Last year and health contributed to Canada’s decision.
Avoid dialysis
A nephrologist of Toronto General Hospital, Dr. David Cherney helped lead the canadian part of the test and said the results suggest that patients are possible to reduce the loss of kidney function before requirement of dialysis or kidney transplant.
In an interview, there is also a senior scientist at the Toronto General Hospital Research Institute, “My patients are afraid of dialysis – dialysis or transplant.”
“I can rarely reduce that risk and thus reduce their anxiety and fear of serious, serious complications. Not to mention all heart disease, which also makes patients extremely afraid.”
Researchers at the University of Toronto have doubled the risk of severe form of vision loss among diabetic and mounjaro, GLP -1, GLP -1, which affects daily activities such as reading and driving.
Dr. Vancouver, an endocrinologist Dr. Ahud ur, who was not involved in the study, said that the results are reliable and Ozapic’s health canada’s acceptance to help prevent kidney fall. “
The UR said, “Kidney disease prevention is a very important target in managing patients with type 2 diabetes and is another tool,” said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia.
The brand name of an injected dose of ozmpic semglutide is a glucagon -like peptide -1 (GLP -1) hormone. The Ozapic was first approved as diabetic drug in Canada in Canada as it reduces blood sugar.
Semaglutide can also reduce appetite. In 2021, Health Canada approved it as a weight loss drug for obese people at high doses sold by Novo Nordisk under Brand Naam Vagovi. Following the lack of global supply, in January 2025, Health Canada stated that the supply of ozmpic and other GLP -1 receptor agonists had stabilized.
Heart safety benefits established
In an email of the Canadian press, Health Canada confirmed that on August 13, it approved the ozmpic “” Type 2 diabetes and chronic kidney disease with a continuous projected glomerular filtration rate (EGFR) in adults with chronic diabetes and chronic kidney disease to reduce the risk of death, end-grain kidney disease and heart. “
Glomerular filtration rate is a remedy that shows how well the kidneys are filtering waste and excess water.
Ozapic is the first GLP -1 drug approved in Canada to protect both kidneys and both Heart In patients with type 2 diabetes, Ur said, given that the heart benefits of Semaglutide have been largely studied.
“The advantage of ozmpic is that you also get weight loss, which is a very important goal for most people (with type 2 diabetes). This is a very exciting combination,” he said.
Some people experience gastrointestinal side effects when they take ozmpic, Ur said, including nausea, vomiting, constipation and diarrhea.
More Serious complications He said that gallbladder inflammation and pancreatitis may include but most side effects are minor, he said.
Ur said that the benefits of slowing down or preventing progressive kidney disease in people suffering from diabetes would surround the risks of minor side effects.
Canadian press health coverage receive support through partnership with Canadian Medical Association. CP is completely responsible for this material.
